1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 8,950 | 9,150 | 04.07. | |
| 8,850 | 9,250 | 03.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| KEYMED BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 26.06. | KEYMED BIO-B (02162): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 26, 2026 | 1 | HKEx | ||
| 05.06. | KEYMED BIO-B Receives USD257 million Upfront Payment from Sale of Ouro Medicines | 4 | AASTOCKS | ||
| 05.06. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT - UPDATE ON DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES | 2 | HKEx | ||
| 05.06. | CMSI: Three Reasons for Recent Underperformance of Pharma Sector vs HSI; Top Picks INNOVENT BIO, HANSOH PHARMA and KEYMED BIO-B | 9 | AASTOCKS | ||
| 29.04. | KEYMED BIO-B (02162): FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | KEYMED BIO-B (02162): (1) GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF AUDITOR; AND (4) ... | 1 | HKEx | ||
| 29.04. | KEYMED BIO-B (02162): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 29.04. | KEYMED BIO-B (02162): 2025 ANNUAL REPORT | 1 | HKEx | ||
| 15.04. | KEYMED BIO-B (02162): SUPPLEMENTAL ANNOUNCEMENT TO DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES | - | HKEx | ||
| 02.04. | A Healthy Return: Drug Spin-off Nets Keymed Up To $320M | 2 | Benzinga.com | ||
| 26.03. | Keymed Biosciences Announces 2025 Annual Results and Business Updates | 369 | PR Newswire | BEIJING, March 26, 2026 /PRNewswire/ -- Keymed Biosciences (HKEX: 02162) announced its 2025 annual results.
Total revenue in 2025 was approximately RMB 720 million, a 67% year-on-year... ► Artikel lesen | |
| 26.03. | KEYMED BIO-B (02162): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 23.03. | KEYMED BIO-B (02162): DISCLOSEABLE TRANSACTION DISPOSAL OF EQUITY INTEREST IN OURO MEDICINES | 1 | HKEx | ||
| 16.03. | KEYMED BIO-B (02162): DATE OF BOARD MEETING | - | HKEx | ||
| 10.03. | KEYMED BIO-B (02162): VOLUNTARY ANNOUNCEMENT - UPDATE ON COLLABORATION WITH ASTRAZENECA ON CORE PRODUCT CMG901 (AZD0901) | - | HKEx | ||
| 27.08.25 | Keymed Biosciences (02162.HK) Reports Strong Interim 2025 Results with Accelerated Commercialization and Robust R&D Momentum | 355 | PR Newswire | CHENGDU, China, Aug. 27, 2025 /PRNewswire/ -- Keymed Biosciences Inc. ("Keymed", 02162.HK) announced impressive interim results for 2025, marked by accelerated commercialization and R&D progress.
Financially... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,30 | -0,18 % | Novo Nordisk sucht Volumen, BioNTech sucht Beweise | Pharmaaktien werden derzeit nicht einheitlich bewertet. Der Markt unterscheidet härter zwischen bereits kommerzialisierten Blockbustern, deren Preise unter Druck geraten, und Biotech-Pipelines, die... ► Artikel lesen | |
| OCUGEN | 1,342 | -0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,550 | -0,31 % | Is Viking Therapeutics Stock Going to $50? Here's What the Bulls and Bears Are Saying | ||
| INFLARX | 2,028 | -2,31 % | InflaRx N.V.: InflaRx Assessing Feasibility of Broadened Strategy for ANCA-Associated Vasculitis in Europe Following EMA Recommendation on Tavneos | InflaRx intends to engage with EMA regarding both vilobelimab and izicopan to evaluate the regulatory path to approval in ANCA-associated vasculitis (AAV)The Company is assessing the most efficient... ► Artikel lesen | |
| EDITAS MEDICINE | 3,120 | -1,89 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 16,760 | -0,24 % | Regulatory tracker: FDA sets decision date for Sarepta's DMD drugs | ||
| CARDIOL THERAPEUTICS | 0,930 | 0,00 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2026 Annual General Meeting of Shareholders | TORONTO, June 25, 2026 /PRNewswire/ - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing... ► Artikel lesen | |
| BASILEA | 59,00 | +0,17 % | David Veitch, CEO Basilea, im Interview | von Robert Jakob Moneycab.com: Herr Veitch, Basilea's Cresemba, ein Arzneimittel gegen Sporenpilze, macht mittlerweile weltweit rund 750 Millionen Dollar Umsatz. Wieviel davon schlägt auf die bottom... ► Artikel lesen | |
| ARROWHEAD PHARMACEUTICALS | 73,88 | +0,65 % | Chardan: Arrowhead Pharmaceuticals ist Top-Pick im Biotech-Sektor vor wichtigen Daten | ||
| TELIX PHARMACEUTICALS | 10,382 | +2,02 % | TELIX PHARMACEUTICALS LIMITED: Ceasing to be a substantial holder | ||
| TWIST BIOSCIENCE | 86,88 | -0,41 % | Cathie Wood's ARK sells Twist Bioscience, buys Circle Internet stock | ||
| ONCO-INNOVATIONS | 0,441 | -1,34 % | Onco-Innovations leitet Studien zur Verstoffwechselung von ONC010 in Hepatozyten und Lebermikrosomen aus drei Tierarten ein | Vancouver, Kanada - 26. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder das "Unternehmen") kündigt die Einleitung von Studien... ► Artikel lesen | |
| REPLIGEN | 121,45 | -2,41 % | BioLife is said to have drawn takeover interest from Repligen | ||
| REVOLUTION MEDICINES | 168,25 | +0,72 % | +422% in einem Jahr: Revolution Medicines nach Bauchspeicheldrüsenkrebs-Durchbruch nicht zu ... | Die Rekordfahrt bei der Aktie von Revolution Medicines hat sich zu Wochenbeginn fortgesetzt. Erstmals in der Börsengeschichte der Biotech-Gesellschaft ist der Börsenwert auf über 40 Milliarden Dollar... ► Artikel lesen | |
| UNIQURE | 37,300 | +0,67 % | uniQure (QURE) Now Trades Above Golden Cross: Time to Buy? |
KEYMED BIOSCIENCES INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,21 % bei einem Aktienkurs von 9,250 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KEYMED BIOSCIENCES INC finden Sie auf Wallstreet Online.